Ionis Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Ionis Pharmaceuticals wird ein jährliches Gewinn- und Umsatzwachstum von 32.9% bzw. 21.9% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 33.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -145.2% betragen.

Wichtige Informationen

32.9%

Wachstumsrate der Gewinne

33.5%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	37.0%
Wachstumsrate der Einnahmen	21.9%
Zukünftige Eigenkapitalrendite	-145.2%
Analystenabdeckung	Good
Zuletzt aktualisiert	18 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

LSE:0JDI - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	957	-429	-422	-274	17
12/31/2025	730	-553	-530	-380	24
12/31/2024	623	-516	-414	-365	24
9/30/2024	803	-359	-374	-352	N/A
6/30/2024	813	-366	-375	-346	N/A
3/31/2024	777	-385	-345	-323	N/A
12/31/2023	788	-366	-336	-308	N/A
9/30/2023	615	-409	-574	-541	N/A
6/30/2023	631	-309	-493	-456	N/A
3/31/2023	576	-329	-405	-377	N/A
12/31/2022	587	-270	-294	-274	N/A
9/30/2022	875	7	110	130	N/A
6/30/2022	849	-28	82	98	N/A
3/31/2022	841	-4	35	54	N/A
12/31/2021	810	-29	13	31	N/A
9/30/2021	661	-608	-96	-75	N/A
6/30/2021	688	-550	-59	-30	N/A
3/31/2021	708	-495	-45	-11	N/A
12/31/2020	729	-444	-5	36	N/A
9/30/2020	933	94	173	216	N/A
6/30/2020	940	145	165	213	N/A
3/31/2020	959	169	188	230	N/A
12/31/2019	1,123	281	309	346	N/A
9/30/2019	821	433	154	183	N/A
6/30/2019	799	402	154	170	N/A
3/31/2019	752	366	679	697	N/A
12/31/2018	600	277	585	603	N/A
9/30/2018	575	-41	485	508	N/A
6/30/2018	548	-38	N/A	563	N/A
3/31/2018	543	9	N/A	65	N/A
12/31/2017	514	19	N/A	174	N/A
9/30/2017	507	42	N/A	127	N/A
6/30/2017	499	52	N/A	122	N/A
3/31/2017	426	-15	N/A	86	N/A
12/31/2016	373	-60	N/A	-112	N/A
9/30/2016	238	-184	N/A	-123	N/A
6/30/2016	176	-227	N/A	-111	N/A
3/31/2016	258	-134	N/A	-12	N/A
12/31/2015	284	-88	N/A	21	N/A
9/30/2015	317	14	N/A	129	N/A
6/30/2015	312	23	N/A	95	N/A
3/31/2015	249	-24	N/A	-4	N/A
12/31/2014	214	-39	N/A	6	N/A
9/30/2014	172	-94	N/A	-79	N/A
6/30/2014	151	-92	N/A	-15	N/A
3/31/2014	132	-90	N/A	42	N/A
12/31/2013	147	-61	N/A	63	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 0JDI wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: 0JDI wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: 0JDI wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: 0JDIDie Einnahmen des Unternehmens (21.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt UK (3.5% pro Jahr).

Hohe Wachstumseinnahmen: 0JDIDie Einnahmen des Unternehmens (21.9% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 0JDI wird voraussichtlich in 3 Jahren unrentabel sein.

Ionis Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Ionis Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year 2024

Ionis Pharmaceuticals, Inc. Reaffirms Financial Guidance for the Year 2024

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2023

Ionis Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2022

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Recent updates

Third quarter 2024 earnings released: US$0.94 loss per share (vs US$1.03 loss in 3Q 2023)

Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome

Astrazeneca and Ionis' Wainzua (Eplontersen) Recommends Approval by the Committee for Medicinal Products for Human Use in the European Union

Ionis Pharmaceuticals, Inc. Announces Zilganersen Granted U.S. FDA Fast Track Designation for People Living with Alexander Disease

Ionis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.

Ionis Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $500.25 million.

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: US$0.45 loss per share (vs US$0.60 loss in 2Q 2023)

Ionis Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year 2024

Ionis Pharmaceuticals, Inc. Announces Positive Detailed Results from the HALOS Study of ION582 in People with Angelman Syndrome

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces olezarsen FCS New Drug Application Accepted for Priority Review and Enrollment in Phase 3 sHTG Program Completed

Ionis Pharmaceuticals, Inc. Presents Positive Results from OASIS-HAE and OASISplus Studies of Investigational Medicine Donidalorsen in Patients with Hereditary Angioedema

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Ionis Pharmaceuticals, Inc. Reaffirms Financial Guidance for the Year 2024

First quarter 2024 earnings released: US$0.98 loss per share (vs US$0.87 loss in 1Q 2023)

Ionis Pharmaceuticals, Inc., Annual General Meeting, Jun 06, 2024

Ionis Presents Positive Results from Phase 3 Balance Study of Olezarsen for Familial Chylomicronemia Syndrome

Ionis Pharmaceuticals, Inc. Announces Positive Results from Phase 2 Study of ION224

Ionis Pharmaceuticals, Inc. Announces Executive Changes

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

Full year 2023 earnings released: US$2.56 loss per share (vs US$1.90 loss in FY 2022)

Ionis Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Grants Orphan Drug Designation to the Investigational Medicine Olezarsen for the Treatment of FCS

Founder recently sold US$1.2m worth of stock

Ionis Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 3 Oasis-Hae Study of Investigational Donidalorsen in Patients with Hereditary Angioedema

Ionis Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Ionis and AstraZeneca's WAINUA

Ionis Pharmaceuticals, Inc. Appoints Michael Yang as a Member of Board

Ionis Pharmaceuticals, Inc. Shares Positive Clinical Update from Ongoing Trial of Ion582 for Angelman Syndrome

Ionis Presents Positive Two-Year Results from the Phase 2 Open-Label Extension Study of Donidalorsen in Patients with Hereditary Angioedema

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: US$1.03 loss per share (vs US$0.33 loss in 3Q 2022)

Ionis Pharmaceuticals, Inc. Announces Positive Olezarsen Topline Results from Phase 3 Study in People with Facilitate Chylomicronemia Syndrome

Second quarter 2023 earnings released: US$0.59 loss per share (vs US$0.74 loss in 2Q 2022)

Ionis Completes Enrollment in Phase 3 Cardio-TTRansform Study in Patients with TTR-Mediated Amyloid Cardiomyopathy

Ionis Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Ionis Pharmaceuticals, Inc. Announces Positive Topline, 85-Week Data from the Phase 3 Neuro-Ttransform Study in Patients with Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Ionis Pharmaceuticals, Inc. Announces New Data Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Medical Needs After Gene Therapy

Ionis Pharmaceuticals, Inc. Announces Positive Donidalorsen Late-Stage Clinical Progress in HAE

First quarter 2023 earnings released: US$0.87 loss per share (vs US$0.46 loss in 1Q 2022)

Full year 2022 earnings released: US$1.90 loss per share (vs US$0.20 loss in FY 2021)

Founder recently sold US$1.0m worth of stock

Ionis Pharmaceuticals, Inc. Announces GSK Has Advanced Bepirovirsen into Phase 3 Development

Ionis Receives FDA Fast Track Designation for Olezarsen in Patients with Familial Chylomicronemia Syndrome

Ionis Pharmaceuticals, Inc. Announces European Medicines Agency Accepts Marketing Authorization Application of Tofersen to Treat Rare, Genetic Form of ALS

Insufficient new directors

Third quarter 2022 earnings released: US$0.33 loss per share (vs US$0.58 loss in 3Q 2021)

Ionis Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2022

Ionis Pharmaceuticals, Inc. Announces Positive Data from GSK's Phase 2b Clinical Study of Bepirovirsen

Ionis Pharmaceuticals, Inc. Presents Positive Phase 2 Data in Patients with IgA Nephropathy At American Society of Nephrology's Kidney Week 2022

Ionis Pharmaceuticals, Inc. Announces Positive Results from Fesomersen Development Program

Oxford Properties Group, Inc. acquired 18.4-Acre Life Science Campus and Corporate Headquarters of Ionis Pharmaceutical in San Diego from Ionis Pharmaceuticals, Inc. (NasdaqGS:IONS).

Ionis Pharmaceuticals, Inc. Provides Update on Development Program Evaluating PCSK9 Antisense Medicine for the Treatment of Hypercholesterolemia

Ionis Pharmaceuticals, Inc. Presents Positive Results from Phase 3 Neuro-Ttransform Study At International Symposium on Amyloidosis

Second quarter 2022 earnings released: US$0.74 loss per share (vs US$0.57 loss in 2Q 2021)

Ionis Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces Positive Topline Results from Phase 2B Clinical Study of Fesomersen

Ionis Pharmaceuticals, Inc. Announces FDA Accepts New Drug Application and Grants Priority Review of Tofersen for A Rare, Genetic Form of ALS

Ionis Announces Enrollment Completion of Phase 3 Lp(a) HORIZON Cardiovascular Outcomes Study of Pelacarsen

Frederick Muto Retires from Ionis Pharmaceuticals, Inc., Effective July 15, 2022

Ionis Partner Licenses Rare Kidney Disease Treatment and Will Advance into Phase 3 Clinical Study

Insufficient new directors

Ionis Pharmaceuticals, Inc. Announces Presentation of Positive Phase 2B Data for Chronic Hepatitis B Treatment At the EASL International Liver Congress™

Ionis Announces Eplontersen Met Co-Primary and Secondary Endpoints in Interim Analysis of the Phase 3 Neuro-Ttransform Study for Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (Attrv-Pn)

Ionis Pharmaceuticals, Inc. Announces Results from the Phase 3 Valor Study and Its Open-Label Extension of tofersen

First quarter 2022 earnings released: US$0.46 loss per share (vs US$0.64 loss in 1Q 2021)

Ionis Pharmaceuticals, Inc., Annual General Meeting, Jun 02, 2022

Ionis and Astrazeneca Announce Positive Data for Etesian Phase 2B Study of Antisense Medicine Targeting PCSK9 at 2022 American College of Cardiology Scientific Session

Biogen Inc. and Ionis Pharmaceuticals, Inc. Announce Topline Phase 1 Study Results of BIIB078 in C9orf72 Amyotrophic Lateral Sclerosis